{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:50:41Z","timestamp":1792633841155,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T00:00:00Z","timestamp":1709596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s11883-024-01193-8","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T06:01:54Z","timestamp":1709618514000},"page":"119-131","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Highlights of Cardiovascular Disease Prevention Studies Presented at the 2023 American Heart Association Scientific Sessions"],"prefix":"10.1007","volume":"26","author":[{"given":"Melody","family":"Hermel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul Mannan Khan","family":"Minhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Inam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly E.","family":"Waldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eventine","family":"Youngblood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Slipczuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Sheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea","family":"Meloche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Khoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S.","family":"Virani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,5]]},"reference":[{"key":"1193_CR1","doi-asserted-by":"publisher","unstructured":"\u2022Lincoff AM, Brown-Frandsen K, Colhoun HM, et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med https:\/\/doi.org\/10.1056\/NEJMoa2307563. Epub ahead of print.\u00a0The SELECT study evaluated whether the addition of semaglutide to standard care would be superior to placebo in reducing the risk of major adverse cardiovascular events (MACE) among patients who were overweight or obese with preexisting CVD who did not have diabetes.","DOI":"10.1056\/NEJMoa2307563"},{"key":"1193_CR2","doi-asserted-by":"crossref","unstructured":"James S, Erlinge D, Storey RF, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid\u00a03(2), EVIDoa2300286 (2024).","DOI":"10.1056\/EVIDoa2300286"},{"key":"1193_CR3","doi-asserted-by":"publisher","unstructured":"Kitt J, Fox R, Frost A, et al. (2023) Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: the POP-HT randomized clinical trial. JAMA. https:\/\/doi.org\/10.1001\/jama.2023.21523. Epub ahead of print.","DOI":"10.1001\/jama.2023.21523"},{"key":"1193_CR4","doi-asserted-by":"publisher","unstructured":"Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, Michael LF, Ruotolo G, Gribble G, Navar AM, Nicholls SJ. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023.\u00a0330(21):2075\u20132083.\u00a0https:\/\/doi.org\/10.1001\/jama.2023.21835.","DOI":"10.1001\/jama.2023.21835"},{"key":"1193_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ahj.2022.12.003","volume":"257","author":"J Liu","year":"2023","unstructured":"Liu J, Wang B, Li Y, Yan X, Ge J, Li J. Rationale and design of the Effects of intensive Systolic blood Pressure lowering treatment in reducing RIsk of vascular evenTs (ESPRIT): A multicenter open-label randomized controlled trial. Am Heart J. 2023;257:93\u2013102.","journal-title":"Am Heart J"},{"issue":"1","key":"1193_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11883-022-01079-7","volume":"25","author":"K Gupta","year":"2023","unstructured":"Gupta K, Hirsch JR, Kalsi J, Patel V, Gad MM, Virani SS. Highlights of cardiovascular disease prevention studies presented at the 2022 American Heart Association Scientific Sessions. Curr Atheroscler Rep. 2023;25(1):31\u201341. https:\/\/doi.org\/10.1007\/s11883-022-01079-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"6","key":"1193_CR7","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11883-023-01103-4","volume":"25","author":"K Gupta","year":"2023","unstructured":"Gupta K, Balachandran I, Foy J, Hermel M, Latif A, Krittanawong C, Slipczuk L, Baloch F, Samad Z, Virani SS. Highlights of cardiovascular disease prevention studies presented at the 2023 American College of Cardiology Conference. Curr Atheroscler Rep. 2023;25(6):309\u201321. https:\/\/doi.org\/10.1007\/s11883-023-01103-4.","journal-title":"Curr Atheroscler Rep"},{"key":"1193_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083\u201391.","journal-title":"Nat Med"},{"key":"1193_CR9","unstructured":"Amit Saha (2023) Coronary Artery Risk Development in Young Adults\u2013Salt Sensitivity of Blood Pressure - CARDIA-SSBP. American College of Cardiology. https:\/\/www.acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2023\/11\/10\/05\/29\/cardia-ssbp. Accessed November 12, 2023."},{"key":"1193_CR10","unstructured":"(2022) Heart Disease and Stroke in Black Women. Go Red for Women. American Heart Association. https:\/\/www.goredforwomen.org\/en\/about-heart-disease-in-women\/facts\/heart-disease-in-african-american-women"},{"issue":"3","key":"1193_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic agent for hypertension. N Engl J Med. 2023;389(3):228\u201338. https:\/\/doi.org\/10.1056\/NEJMoa2208391.","journal-title":"N Engl J Med"},{"issue":"1","key":"1193_CR12","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12916-021-02208-w","volume":"20","author":"M Xu","year":"2022","unstructured":"Xu M, Zhu X, Wu J, et al. PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b\/2 study. BMC Med. 2022;20(1):13. https:\/\/doi.org\/10.1186\/s12916-021-02208-w.","journal-title":"BMC Med"},{"key":"1193_CR13","unstructured":"Qiang L, Du X, Wang Z, et al (2023) Recaticimab add-on therapy in patients with non-familial hypercholesterolaemia and mixed hyperlipidemia (remain-2): a multicenter, randomized, double-blind, placebo-controlled phase 3 trial [abstract].\u00a0Presented at\u00a0American Heart Association: Scientific Sessions."},{"key":"1193_CR14","doi-asserted-by":"publisher","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, et al (2022) Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Catapano AL. Eur Heart J. https:\/\/doi.org\/10.1016\/j.pcad.2022.01.002","DOI":"10.1016\/j.pcad.2022.01.002"},{"key":"1193_CR15","doi-asserted-by":"publisher","unstructured":"\u2022\u2022SS Virani ML Koschinsky L Maher et al 2022 Global think tank on the clinical considerations and management of lipoprotein(a): the top questions and answers regarding what clinicians need to know Prog Cardiovasc Dis\u00a0\u00a0https:\/\/doi.org\/10.1016\/j.pcad.2022.01.002. Summarized the findings from a global think tank convened to provide practical answers to key questions pertaining to Lp(a).","DOI":"10.1016\/j.pcad.2022.01.002"},{"issue":"22","key":"1193_CR16","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132(22):2167\u201392. https:\/\/doi.org\/10.1161\/CIR.0000000000000297.","journal-title":"Circulation"},{"key":"1193_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-015-0491-z","author":"A Brautbar","year":"2015","unstructured":"Brautbar A, Leary E, Rasmussen K, et al. Genetics of familial hypercholesterolemia. Curr atheroscler Rep. 2015. https:\/\/doi.org\/10.1007\/s11883-015-0491-z.","journal-title":"Curr atheroscler Rep"},{"issue":"3","key":"1193_CR18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.122.062132","volume":"147","author":"RG Lee","year":"2023","unstructured":"Lee RG, Mazzola AM, Braun MC, Platt C, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation. 2023;147(3):242\u201353. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.062132.","journal-title":"Circulation"},{"key":"1193_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.02.042","author":"NS Maitra","year":"2022","unstructured":"Maitra NS, Mahtta D, Navaneethan S, et al. A mistake not to be repeated: what can we learn from the underutilization of statin therapy for efficient dissemination of cardioprotective glucose lowering agents? Currently Cardiol Rep. 2022. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.042.","journal-title":"Currently Cardiol Rep"},{"key":"1193_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.02.042","author":"SS Virani","year":"2022","unstructured":"Virani SS, Ballantyne CM, Petersen LA. Guideline-concordant statin therapy use in secondary prevention: should the medical community wait for divine intervention. J Am Coll Cardiol. 2022. https:\/\/doi.org\/10.1016\/j.jacc.2022.02.042.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"1193_CR21","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.ahj.2005.06.034","volume":"151","author":"PC Austin","year":"2006","unstructured":"Austin PC, Mamdani MM, Juurlink DN, Alter DA, Tu JV. Missed opportunities in the secondary prevention of myocardial infarction: an assessment of the effects of statin underprescribing on mortality. Am Heart J. 2006;151(5):969\u201375.","journal-title":"Am Heart J"},{"issue":"22","key":"1193_CR22","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1056\/nejmoa1511939","volume":"373","author":"The SPRINT Research Group","year":"2015","unstructured":"\u2022\u2022The SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103\u201316. https:\/\/doi.org\/10.1056\/nejmoa1511939. Intensive blood pressure control in patients at high risk for cardiovascular disease demonstrated improved cardiovascular outcomes and overall survival compared to standard therapy.","journal-title":"N Engl J Med"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01193-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-024-01193-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-024-01193-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T08:22:10Z","timestamp":1712132530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-024-01193-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1193"],"URL":"https:\/\/doi.org\/10.1007\/s11883-024-01193-8","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,5]]},"assertion":[{"value":"8 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Melody Hermel, Andrew Chiou, Abdul Mannan Khan Minhas, Maha Inam, Carly E. Waldman, Eventine Youngblood, Sandeep Mehta, Sana Sheikh, Chelsea Meloche, and Adeel Khoja declare no conflicts of interest. Leandro Slipczuk: Consulting honorarium for lectures from Amgen and Philips and for advisory board participation from Bristol Myers Squibb. Institutional grants from Amgen and Philips. Site PI for V-INITIATE and Ocean(a) trials. Salim S. Virani: Honorarium, American College of Cardiology (Associate Editor for Innovations, acc.org), and Section Editor for Current Atherosclerosis Reports and Current Cardiology Reports.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}